FDA Advisory Committee Discusses Clinical Data Package for BioMarin’s Kyndrisa(TM) (drisapersen) for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Go back to FDA Advisory Committee Discusses Clinical Data Package for BioMarin’s Kyndrisa(TM) (drisapersen) for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 56.50 +0.60 (1.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.90 | 52 Week High | $108.96 | |||
| Open | $55.80 | 52 Week Low | $62.12 | |||
| Day High | $57.00 | P/E | N/A | |||
| Day Low | $55.74 | EPS | $-1.27 | |||
| Volume | 1,987,924 | |||||
